As mentioned above, siramesine specifically targets a variety of cancer cell lines through ASM inhibition (50, 51), and its mechanism of action appears to involve inhibition of ASM binding to and activation by the acidic lysosome-specific lipid bis(monoacylglycero)phosphate (BMP) within ILVs (51). Here, SMPD1 is linked to cancer.